AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02291783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTL0009936 placebo
Description: Placebo single dose
Study NCT04548700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
Description: Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle.
Study NCT04548700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
Description: Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day.
Study NCT04222894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study NCT04222894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Participants will be asked to continue their usual diets for the 12-week study period.
Study NCT02316353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor
Study NCT01101958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Chartis System
Description: The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
Study NCT01101958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endobronchial Valve (EBV) Treatment
Description: The endobronchial valve is designed to induce target lobe volume reduction.
Study NCT01098253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: Factors affecting adherence are addressed using a problem solving process.
Study NCT01585779 — intervention group
Intervention type: DEVICE
Intervention: Contour 3D® implant for tricuspid valve repair
Description: Tricuspid annuloplasty ring
Study NCT01585779 — intervention group
Intervention type: DEVICE
Intervention: Tri-Ad® implant for tricuspid valve repair
Description: Tricuspid annuloplasty ring
Study NCT03840044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold air exercise test
Description: Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
Study NCT01034982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 20 mg
Study NCT02713126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
Study NCT02713126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Description: administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
Study NCT01034982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 60 mg
Study NCT02644096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: counselling and support after discharge from hospital
Description: patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
Study NCT00540241 — intervention group
Intervention type: DRUG
Intervention: Pemetrexed
Description: in-label use
Study NCT04169984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofunctional Therapy
Description: Isometric, isokinetic and isotonic exercises for the upper airway muscles.
Study NCT04169984 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exercises that do not alter the function or morphology of the upper airway.
Study NCT02026674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloRite
Description: Disposable home use urine flow meter.
Study NCT03046927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
Study NCT03046927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
Study NCT01766804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
Study NCT01766804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02092636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIR/US Diagnostic Group
Description: Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
Study NCT02092636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIR/US Neoadjuvant Chemotherapy Group
Description: Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
Study NCT02092636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NIR/US Process Validation Group
Description: Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
Study NCT00573612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Subjects will receive Motivational Interviewing telephone counseling.
Study NCT02590003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02590003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02590003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT03495219 — intervention group
Intervention type: PROCEDURE
Intervention: Esophageal Manometry
Description: A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
Study NCT01517711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
Study NCT01517711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
Study NCT01120002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamibarotene
Description: Two Tamibarotene 2 mg or placebo tablet per day, once daily.
Study NCT02713126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accelerometer
Description: External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
Study NCT02713126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
Study NCT02713126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac Exercise Training
Description: Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
Study NCT02713126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Exercise Training
Description: Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive nutrition education
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive nutrition education
Study NCT03751449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete home-based aerobic and resistance exercise program
Study NCT03751449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Complete home-based aerobic and resistance exercise program
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03751449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00677469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: 2 grams BID
Study NCT00677469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: 1 gram BID
Study NCT00677469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: 1 gram BID
Study NCT01120002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Tamibarotene 2 mg or placebo tablet per day, once daily.
Study NCT03800797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium hydrogel patch
Description: 100 mg per day
Study NCT03800797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen sodium tablet
Description: 60 mg t.i.d.
Study NCT01471470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Description: Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
Study NCT04704297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.
Description: We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
Study NCT04704297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.
Description: Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
Study NCT04704297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
Description: 60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
Study NCT02349659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT03714984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre operative exercise
Description: After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
Study NCT03714984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
Study NCT02183493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Study NCT02183493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT01682317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Frequency
Description: Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
Study NCT01374321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRO40303
Description: 6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
Study NCT01374321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
Study NCT00942370 — intervention group
Intervention type: DEVICE
Intervention: non invasive mechanomyographic device based on a 3 axes accelerometer
Description: This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person.
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT02574078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Palliative radiation, palliative surgery and/or other best supportive care treatments
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Study NCT02574078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT03085459 — intervention group
Intervention type: BEHAVIORAL
Intervention: work Time
Description: nurse got qualification certificate and the working time
Study NCT00062855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Study NCT00062855 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Modified Neuroblastoma Cells
Description: The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp
Description: Brenetafusp IV infusions
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and pembrolizumab
Description: Brenetafusp and pembrolizumab IV infusions
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and chemotherapy
Description: Brenetafusp and chemotherapy IV infusions
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and monoclonal antibodies and chemotherapy
Description: Brenetafusp and a monoclonal antibody therapy and chemotherapy
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and tebentafusp
Description: Brenetafusp and tebentafusp IV infusions
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and bevacizumab
Description: Brenetafusp and bevacizumab IV infusions
Study NCT04262466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brenetafusp and kinase inhibitors
Description: Brenetafusp and oral kinase inhibitors
Study NCT03166852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-training
Description: 5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
Study NCT00660972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablet taken orally twice daily
Study NCT00660972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
Study NCT05176340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Thematic Nursing Care Action Modules (STNC-AM)
Description: The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module.